Michael R. Megna - 04 Oct 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: CHIEF ACCOUNTING OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol: KNSA
Transactions as of: 04 Oct 2022
Net transactions value: -$740
Form type: 4
Filing time: 06 Oct 2022, 16:18:43 UTC
Previous filing: 06 Sep 2022
Next filing: 20 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+175	+2.4%		7,466	04 Oct 2022	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	$740	-52	-0.7%	$14.23	7,414	04 Oct 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-175	-25%	$0.000000	525	04 Oct 2022	Class A Common Share	175		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021.